Indivior PLC’s (INDV) Buy Rating Reiterated at Numis Securities Ltd
Numis Securities Ltd reaffirmed their buy rating on shares of Indivior PLC (LON:INDV) in a report published on Monday. They currently have a GBX 370 ($4.83) price objective on the specialty pharmaceutical company’s stock.
A number of other equities analysts also recently issued reports on the stock. Stifel Nicolaus raised their price objective on shares of Indivior PLC from GBX 310 ($4.05) to GBX 350 ($4.57) and gave the stock a buy rating in a report on Monday, July 11th. Morgan Stanley raised shares of Indivior PLC to an overweight rating and raised their price objective for the stock from GBX 190 ($2.48) to GBX 280 ($3.65) in a report on Tuesday, June 14th. Jefferies Group reissued a buy rating and issued a GBX 330 ($4.31) price objective on shares of Indivior PLC in a report on Wednesday, August 17th. Deutsche Bank AG reissued a buy rating and issued a GBX 290 ($3.79) price objective on shares of Indivior PLC in a report on Monday, August 1st. Finally, Citigroup Inc. cut shares of Indivior PLC to a neutral rating and raised their target price for the stock from GBX 230 ($3.00) to GBX 280 ($3.65) in a research note on Tuesday, July 19th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of GBX 346.43 ($4.52).
Indivior PLC (LON:INDV) opened at 305.40 on Monday. The company’s 50-day moving average is GBX 317.18 and its 200 day moving average is GBX 232.67. Indivior PLC has a 12-month low of GBX 126.60 and a 12-month high of GBX 365.00. The stock’s market capitalization is GBX 2.20 billion.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.